These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27546827)

  • 1. The future of renal denervation.
    Esler M; Guo L
    Auton Neurosci; 2017 May; 204():131-138. PubMed ID: 27546827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal denervation for treatment of drug-resistant hypertension.
    Esler M
    Trends Cardiovasc Med; 2015 Feb; 25(2):107-15. PubMed ID: 25467242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
    Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
    Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.
    Persu A; Kjeldsen S; Staessen JA; Azizi M
    Curr Hypertens Rep; 2016 Jan; 18(1):6. PubMed ID: 26739586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Percutaneous renal denervation as a new method of treatment of resistant arterial hypertension].
    Mach-Jamińska A; Sułowicz W
    Przegl Lek; 2012; 69(11):1215-9. PubMed ID: 23646450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal denervation for hypertension: observations and predictions of a founder.
    Esler M
    Eur Heart J; 2014 May; 35(18):1178-85. PubMed ID: 24598982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
    Epstein M; de Marchena E
    J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous renal sympathetic denervation: 2013 and beyond.
    Froeschl M; Hadziomerovic A; Ruzicka M
    Can J Cardiol; 2014 Jan; 30(1):64-74. PubMed ID: 24365191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Denervation: Where to Now?
    Wimmer NJ; Mauri L
    Curr Cardiol Rep; 2015 Dec; 17(12):116. PubMed ID: 26482759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.
    Fischell TA; Ebner A; Gallo S; Ikeno F; Minarsch L; Vega F; Haratani N; Ghazarossian VE
    JACC Cardiovasc Interv; 2016 Mar; 9(6):589-98. PubMed ID: 27013159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal artery denervation for treating refractory hypertension].
    Benamer H; Louvard Y; Garot P; Unterseeh T; Hovasse T; Lefèvre T; Chevalier B; Morice MC
    Ann Cardiol Angeiol (Paris); 2011 Dec; 60(6):354-60. PubMed ID: 22040858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal sympathetic denervation: hypertension therapy and beyond.
    Williams PD; Whitbourn R
    Expert Rev Med Devices; 2013 May; 10(3):329-38. PubMed ID: 23668705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension.
    Hering D; Marusic P; Walton AS; Duval J; Lee R; Sata Y; Krum H; Lambert E; Peter K; Head G; Lambert G; Esler MD; Schlaich MP
    Int J Cardiol; 2016 Jan; 202():388-93. PubMed ID: 26432488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
    Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal denervation for the treatment of hypertension: Making a new start, getting it right.
    Weber MA; Kirtane A; Mauri L; Townsend RR; Kandzari DE; Leon MB
    Catheter Cardiovasc Interv; 2015 Nov; 86(5):855-63. PubMed ID: 26097069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.